Начало・Списък с акции・Corcept Therapeutics Inc

Corcept Therapeutics Inc

Затворен

СекторЗдравеопазване

109.34 -2.43

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

108.84

Максимум

112.91

Ключови измерители
By Trading Economics
Приходи	-130M -32M
Продажби	-37M 165M
P/E Средно за сектора	260.343 64.641
EPS	-0.3
Марж на печалбата	-19.26
Служители	730
EBITDA	-55M -44M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+8.69% upside

Дивиденти
By Acuity
Следващи печалби	3.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	4.8B 9.8B
Предишно отваряне	111.77
Предишно затваряне	109.34

Corcept Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.08.2026 г., 19:16 ч. UTC

Corcept Therapeutics Inc shares are lower today, continuing a decline seen over the past three trading days. No specific news was identified for the drop.

3.08.2026 г., 20:02 ч. UTC

Corcept Therapeutics Inc shares are lower today amid a decline in the Pharmaceuticals sub-sector, with unusually high trading volume noted.

31.07.2026 г., 22:26 ч. UTC

Corcept Therapeutics shares are higher in after-market hours, peaking shortly after Friday's close despite no specific news to explain the movement.

30.07.2026 г., 23:11 ч. UTC

Corcept Therapeutics shares traded lower in after-market hours, reflecting broader market uncertainty following the Federal Reserve's interest rate decision.

29.07.2026 г., 23:41 ч. UTC

Social Media

News

Corcept Therapeutics shares are trading higher in after-market hours following strong second-quarter results, with revenue of $256.1 million and raised full-year guidance.

28.07.2026 г., 19:46 ч. UTC

News

Corcept Therapeutics shares are higher ahead of Q2 earnings tomorrow, with analysts expecting revenue growth to slow to 8.4% year-on-year.

27.07.2026 г., 23:46 ч. UTC

Shares of Corcept Therapeutics Inc declined in after-hours trading, dipping to a low shortly after the market reopened. No specific news was identified.

24.07.2026 г., 21:01 ч. UTC

Corcept Therapeutics shares are lower in after-market trading, reflecting broader negative sentiment following earnings reports from major companies like Tesla and Alphabet.

22.07.2026 г., 19:51 ч. UTC

Corcept Therapeutics Inc shares are lower today, breaking a trend of higher closes. Broader market sentiment is affected by rising crude oil prices and geopolitical tensions.

21.07.2026 г., 17:06 ч. UTC

Corcept Therapeutics Inc is trading higher today, reflecting broader market trends as regional indices like the Nikkei 225 also show gains.

20.07.2026 г., 18:13 ч. UTC

Social Media

Corcept Therapeutics shares are higher today, boosted by FDA approval of Lifyorli and increased trading volume amid heightened investor interest.

Сравнение с други в отрасъла

Ценова промяна

Corcept Therapeutics Inc Прогноза

Ценова цел

By TipRanks

8.69% нагоре

12-месечна прогноза

Среден 122.6 USD 8.69%

Висок 165 USD

Нисък 50 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Corcept Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Corcept Therapeutics Inc през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.